Objective： The aim of the present study is to explore the expression of a specific marker of breast cancer, small breast epithefial mucin （SBEM） mRNA, in peripheral blood and to investigate its significance. Method...Objective： The aim of the present study is to explore the expression of a specific marker of breast cancer, small breast epithefial mucin （SBEM） mRNA, in peripheral blood and to investigate its significance. Methods： The expressions of SBEM-mRNA in peripheral blood of 67 patients with breast cancer, 16 patients with benign breast disease, and 20 normal healthy volunteers were detected with nested reverse transcription-polymerase chain reaction （Nested-RT-PCR）. Results： SBEMomRNA was negative in healthy individuals and patients with benign breast tumor, but 50.7%（34/67） of breast cancer patients showed positive expression of SBEM-mRNA in peripheral blood, of whom 25%（2/8） were in stage Ⅰ, 45.8%（11/24） in stage Ⅱ, 43.75%（11/24） in stage Ⅲ and 73.7（14/19） in stage Ⅳ. The positive rate in stage Ⅳ was higher than that in stage Ⅰ, Ⅱ, Ⅲ （P〈0.05）. Expressions of SBEM-mRNA had no correlation with age, carcinoma size, pathological type, ER and PR state （P〉0.05）. Concision： SBEM-mRNA is specifically expressed in breast cancer and it may act as a marker for the detection of of breast cancer.展开更多
基金This work was supported by the Natural Science Foundation of Guangxi Province (No. 0640161).
文摘Objective： The aim of the present study is to explore the expression of a specific marker of breast cancer, small breast epithefial mucin （SBEM） mRNA, in peripheral blood and to investigate its significance. Methods： The expressions of SBEM-mRNA in peripheral blood of 67 patients with breast cancer, 16 patients with benign breast disease, and 20 normal healthy volunteers were detected with nested reverse transcription-polymerase chain reaction （Nested-RT-PCR）. Results： SBEMomRNA was negative in healthy individuals and patients with benign breast tumor, but 50.7%（34/67） of breast cancer patients showed positive expression of SBEM-mRNA in peripheral blood, of whom 25%（2/8） were in stage Ⅰ, 45.8%（11/24） in stage Ⅱ, 43.75%（11/24） in stage Ⅲ and 73.7（14/19） in stage Ⅳ. The positive rate in stage Ⅳ was higher than that in stage Ⅰ, Ⅱ, Ⅲ （P〈0.05）. Expressions of SBEM-mRNA had no correlation with age, carcinoma size, pathological type, ER and PR state （P〉0.05）. Concision： SBEM-mRNA is specifically expressed in breast cancer and it may act as a marker for the detection of of breast cancer.
